Literature DB >> 23312565

Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort.

Alice Egerton1, Christopher A Chaddock, Toby T Winton-Brown, Michael A P Bloomfield, Sagnik Bhattacharyya, Paul Allen, Philip K McGuire, Oliver D Howes.   

Abstract

BACKGROUND: Using positron emission tomography (PET), we previously observed increases in 3,4-dihydroxy-6-[(18)F]fluoro-L-phenylalanine ((18)F-DOPA) uptake in the striatum of subjects at ultra-high risk (UHR) for psychosis, indicating elevated presynaptic dopamine synthesis capacity. The purpose of this study was to test if this finding would be replicated in a second UHR cohort.
METHODS: (18)F-DOPA PET was used to estimate dopamine synthesis capacity in the striatum of an entirely new cohort of 26 individuals at UHR for psychosis (14 males, mean±SD age = 22.7±4.7 years) and 20 healthy volunteers matched for age and gender (11 males, mean±SD age = 24.5±4.5 years).
RESULTS: Dopamine synthesis capacity was elevated in the whole [t(44) = 2.6; p = .01, effect size = .81] and associative striatum [t(44) = 2.6; p = .01, effect size = .73] of UHR compared with control subjects. When the two samples were combined to give a final sample of 32 control and 50 UHR subjects, the higher levels of dopamine synthesis capacity in the UHR group reached significance across the whole [F(1,81) = 11.0; p = .001], associative [F(1,81) = 12.7; p = .001], and sensorimotor [F(1,81) = 4.7; p = .03], but not the limbic [F(1,81) = 2.1; p = .2], striatum.
CONCLUSIONS: The findings indicate that elevated dopamine synthesis capacity in the dorsal striatum is a robust feature of individuals at UHR for psychosis and provide further evidence that dopaminergic abnormalities precede the onset of psychosis.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23312565     DOI: 10.1016/j.biopsych.2012.11.017

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  95 in total

1.  [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro].

Authors:  M Lambert; C Correll
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

Review 2.  Stress during critical periods of development and risk for schizophrenia.

Authors:  Felipe V Gomes; Xiyu Zhu; Anthony A Grace
Journal:  Schizophr Res       Date:  2019-01-30       Impact factor: 4.939

3.  Common Variation in the DOPA Decarboxylase (DDC) Gene and Human Striatal DDC Activity In Vivo.

Authors:  Daniel P Eisenberg; Philip D Kohn; Catherine E Hegarty; Angela M Ianni; Bhaskar Kolachana; Michael D Gregory; Joseph C Masdeu; Karen F Berman
Journal:  Neuropsychopharmacology       Date:  2016-02-29       Impact factor: 7.853

4.  Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.

Authors:  Marco Colizzi; Conrad Iyegbe; John Powell; Gianluca Ursini; Annamaria Porcelli; Aurora Bonvino; Paolo Taurisano; Raffaella Romano; Rita Masellis; Giuseppe Blasi; Craig Morgan; Katherine Aitchison; Valeria Mondelli; Sonija Luzi; Anna Kolliakou; Anthony David; Robin M Murray; Alessandro Bertolino; Marta Di Forti
Journal:  Schizophr Bull       Date:  2015-03-31       Impact factor: 9.306

Review 5.  Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features.

Authors:  Jennifer K Forsyth; David A Lewis
Journal:  Trends Cogn Sci       Date:  2017-07-25       Impact factor: 20.229

6.  Psychosis risk is associated with decreased white matter integrity in limbic network corticostriatal tracts.

Authors:  Kelsey T Straub; Jessica P Y Hua; Nicole R Karcher; John G Kerns
Journal:  Psychiatry Res Neuroimaging       Date:  2020-05-15       Impact factor: 2.376

7.  Probabilistic Category Learning and Striatal Functional Activation in Psychosis Risk.

Authors:  Nicole R Karcher; Jessica P Y Hua; John G Kerns
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

Review 8.  Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia.

Authors:  Nao Chuhma; Susana Mingote; Abigail Kalmbach; Leora Yetnikoff; Stephen Rayport
Journal:  Biol Psychiatry       Date:  2016-07-12       Impact factor: 13.382

Review 9.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

Review 10.  An Integrative Perspective on the Role of Dopamine in Schizophrenia.

Authors:  Tiago V Maia; Michael J Frank
Journal:  Biol Psychiatry       Date:  2016-06-01       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.